| 1 | Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial | The Lancet | Amy E. Colson, Anthony Mills et al. | 1 |
| 2 | Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States | AIDS Research and Therapy | Gerald Pierone, Jennifer S Fusco et al. | 1 |
| 3 | Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents | Open Forum Infectious Diseases | Anthony Mills, Kathy L. Schulman et al. | 3 |
| 4 | 1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine | Open Forum Infectious Diseases | Indira Brar, Peter Ruane et al. | 3 |
| 5 | Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide | AIDS | Paul E. Sax, Edwin DeJesus et al. | 7 |
| 6 | Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment | AIDS Research and Human Retroviruses | Edwin DeJesus, Sorana Segal‐Maurer et al. | 67 |
| 7 | Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study | The Lancet HIV | Edwin DeJesus, Moti Ramgopal et al. | 37 |
| 8 | Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial breakdown → | The Lancet | Joel E. Gallant, Adriano Lazzarin et al. | 257 |
| 9 | Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice | Clinical Drug Investigation | Philip Lackey, Anthony Mills et al. | 4 |
| 10 | Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF | Patient | Anthony Mills, Will Garner et al. | 11 |
| 11 | Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy | JAIDS Journal of Acquired Immune Deficiency Syndromes | Anthony Mills, Gordon Crofoot et al. | 121 |
| 12 | Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis | AIDS Patient Care and STDs | Georg M. N. Behrens, Bart Rijnders et al. | 23 |
| 13 | Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies | HIV Clinical Trials | Mark Nelson, Richard Elion et al. | 46 |
| 14 | Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens | HIV Clinical Trials | Anthony Mills, Calvin Cohen et al. | 61 |
| 15 | Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks | The Lancet | Paul E. Sax, Edwin DeJesus et al. | 335 |
| 16 | A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients | International Journal of Clinical Practice | E DeJesus, Anthony Mills et al. | 20 |
| 17 | Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals | Current HIV Research | Patrick Yéni, Anthony Mills et al. | 2 |
| 18 | ARTEMIS: Efficacy and Safety of Darunavir/ritonavir (DRV/r) 800/100 mg Once-daily vs Lopinavir/ritonavir (LPV/r) in Treatment-naïve, HIV-1-infected Patients at 96 Wks | 46th Annual Meeting | Anthony Mills | 1 |
| 19 | Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial | The Lancet | José Valdez Madruga, Pedro Cahn et al. | 403 |
| 20 | Seminatrix pygaea . Diet. | Herpetological review | Travis J. Ryan, Anthony Mills et al. | 2 |